Active — Not RecruitingNot Applicable

Cascade Testing in Families With Newly Diagnosed Hereditary Breast and Ovarian Cancer Syndrome

United States118 participantsStarted 2019-03-01

Plain-language summary

Identification of BRCA mutations in ovarian cancer patients may help guide cancer therapies, prognosis, post-operative screening, and other preventative treatments beyond the initial diagnosis. Likewise, genetic testing of ovarian cancer patients for these germline mutations provides invaluable information for families regarding cancer risk, genetic testing, and subsequently indication for risk-reducing surgery. Cascade testing provides a unique opportunity to identify carriers of a deleterious BRCA mutation which can allow for surgical and chemoprevention of prevention of ovarian cancer. There is currently no literature on the rates of referral for the family members.

Who can participate

Age range18 Years – 99 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * All subjects must have a diagnosis of epithelial ovarian cancer, Fallopian tube caner or primary peritoneal cancer with a known pathogenic genetic mutation. * All subjects must agree to participate. * All subjects must have first or second degree relatives who have not been diagnosed with the same genetic mutation. * A previous diagnosis of cancer in the subject's first or second degree relative is allowed. Exclusion Criteria: * Subjects whose first and/or second degree relatives have already been tested with the subject's known mutations, and no other viable family members are available for testing.

What they're measuring

Establishing the CASCADE Cohort

Timeframe: 1 Year

Trial details

NCT IDNCT04009148

SponsorNYU Langone Health

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2025-06-11

View on ClinicalTrials.gov More BRCA-Mutated Ovarian Carcinoma trials